二酰甘油激酶ε突变相关肾病的表型谱
该研究报道了8个无亲缘关系家系中的10例DGKE肾病新患者,并结合既往所有已发表病例,刻画了DGKE突变相关肾病(HUS/MPGN)的表型谱与结局。多数患者表现为伴蛋白尿的HUS,部分呈无TMA的MPGN,亦有HUS/MPGN重叠;多数为缓慢进展的蛋白尿性肾病,80%患者诊断后10年内未进展至ESRD。未观察到明确基因型-表型相关性,抗补体治疗获益存疑,肾移植可能可行。
要点
- DGKE肾病可表现为HUS、MPGN或两者重叠,HUS多起病于1岁内但非仅限婴儿期。
- 多数患者呈缓慢进展的蛋白尿性肾病,80%诊断后10年内未达ESRD。
- 未观察到明确基因型-表型相关性,抗补体治疗获益存疑,肾移植未见移植后复发。
核心结论
- DGKE肾病患者未观察到明确基因型-表型相关性,提示存在其他因素介导表型异质性。
- 抗补体治疗获益存疑,但肾移植可能是该病的可行治疗选择。
研究设计与样本
- 研究报道8个无亲缘关系家系中的10例DGKE肾病新患者,并与既往所有已发表病例合并分析。
- 采用病例系列结合文献汇总的方法刻画DGKE肾病的表型谱与结局。
主要发现
- 多数患者表现为HUS伴蛋白尿,部分患者呈无TMA的MPGN临床与组织学模式。
- 首次报道2例临床与组织学HUS/MPGN重叠患者。
- DGKE-HUS典型起病于生后第一年,但并非仅局限于婴儿期,病毒感染常为HUS发作的前驱触发因素。
- 部分DGKE-HUS患者可见补体激活迹象,但补体激活的作用尚不明确。
- 多数患者发展为缓慢进展的蛋白尿性肾病,80%患者诊断后10年内未发生ESRD;许多患者未经特殊治疗即获HUS缓解,少数患者在补体通路完全抑制下仍出现HUS复发;5例接受肾移植,未见移植后复发报告。
临床怎么用
- 对早发HUS或MPGN患者应考虑DGKE突变相关肾病,注意HUS与MPGN可重叠出现。
- 多数DGKE肾病患者病程缓慢进展,应长期监测蛋白尿与肾功能。
- 抗补体治疗对该病的获益尚不明确,肾移植可作为可行的治疗选择且未见移植后复发。
局限性
- 本研究为病例系列结合既往文献汇总,样本量有限。
- 补体激活在DGKE-HUS中的作用尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The recent discovery of mutations in the gene encoding diacylglycerol kinase ε (DGKE) identified a novel pathophysiologic mechanism leading to HUS and/or MPGN. We report ten new patients from eight unrelated kindreds with DGKE nephropathy. We combined these cases with all previously published cases to characterize the phenotypic spectrum and outcomes of this new disease entity. Most patients presented with HUS accompanied by proteinuria, whereas a subset of patients exhibited clinical and histologic patterns of MPGN without TMA. We also report the first two patients with clinical and histologic HUS/MPGN overlap. DGKE-HUS typically manifested in the first year of life but was not exclusively limited to infancy, and viral triggers frequently preceded HUS episodes. We observed signs of complement activation in some patients with DGKE-HUS, but the role of complement activation remains unclear. Most patients developed a slowly progressive proteinuric nephropathy: 80% of patients did not have ESRD within 10 years of diagnosis. Many patients experienced HUS remission without specific treatment, and a few patients experienced HUS recurrence despite complete suppression of the complement pathway. Five patients received renal allografts, with no post-transplant recurrence reported. In conclusion, we did not observe a clear genotype-phenotype correlation in patients with DGKE nephropathy, suggesting additional factors mediating phenotypic heterogeneity. Furthermore, the benefits of anti-complement therapy are questionable but renal transplant may be a feasible option in the treatment of patients with this condition.
引用
- Azukaitis K, Simkova E, Majid MA, et al. The Phenotypic Spectrum of Nephropathies Associated with Mutations in Diacylglycerol Kinase ε. J Am Soc Nephrol. 2017. PMID: 28526779. doi:10.1681/ASN.2017010031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。